Group 1 - The company is currently undergoing a strategic transformation, which has led to short-term performance pressure due to business restructuring and increased R&D investment [1] - The company has implemented several improvement measures, including focusing on core business, enhancing risk management, promoting smart healthcare innovation, and improving operational efficiency to drive steady performance improvement [1] - The company has stated that it has not encountered any risk of delisting and appreciates the attention from investors [1]

Core Viewpoint - Seer Medical (603716) has experienced a significant decline in stock price, closing at 22.12 yuan, down 12.47% from the previous week, with a current market capitalization of 4.65 billion yuan [1] Group 1: Trading Information - On January 28, Seer Medical executed a block trade with a transaction amount of 22 million yuan [2] Group 2: Shareholder Changes - Shareholder Shanghai Angze Private Fund Management Co., Ltd. reduced its holdings by 1.5 million shares from December 12, 2025, to January 28, 2026, representing 0.7137% of the total share capital. The total reduction amounted to 3,091,200 shares, or 1.47% of the total share capital, with a remaining holding of 4.29% [3][5] Group 3: Performance Disclosure - Seer Medical anticipates a net loss attributable to shareholders for the year 2025 ranging from 160 million yuan to 209 million yuan, with a net loss excluding non-recurring gains and losses expected between 180 million yuan and 230 million yuan. The anticipated loss is primarily due to a decline in operating income, increased R&D expenses, and impairment of credit and goodwill [4][5][7]

Core Viewpoint - The medical consumables supply chain (SPD) sector experienced a decline of 1.65% on January 30, with major losses led by Saili Medical, while the overall market indices also fell [1][2]. Group 1: Market Performance - The Shanghai Composite Index closed at 4117.95, down 0.96%, and the Shenzhen Component Index closed at 14205.89, down 0.66% [1]. - The SPD sector's individual stock performance showed varied results, with Wenlong Technology rising by 3.69% to a closing price of 25.01, while Saili Medical fell by 4.57% to 22.12 [1][2]. Group 2: Trading Volume and Value - The trading volume for Wenlong Technology was 21,800 hands with a transaction value of 54.02 million yuan, while Saili Medical had a trading volume of 128,200 hands and a transaction value of 286 million yuan [1][2]. Group 3: Capital Flow - The SPD sector saw a net outflow of 231 million yuan from main funds, while retail investors contributed a net inflow of 243 million yuan [2]. - The capital flow data indicated that major funds had a negative net inflow for several companies, including Guoyao Co. and Kangdelai, while retail investors showed positive net inflows for companies like Guoyao Co. and Da Jia Wei Kang [3].

Group 1 - Jintian Co., Ltd. plans to increase its shareholding by an amount between 50 million to 100 million yuan [1] - Jinpu Garden expects a full-year loss of 260 million to 210 million yuan for 2025 [1] - Hebang Biotechnology's shareholder intends to reduce its holdings by no more than 2% of the repurchased shares [1] Group 2 - Shunbo Alloy has received an administrative regulatory decision from the Chongqing Securities Regulatory Bureau due to inaccurate financial disclosures [1] - Mars Man expects a loss of 370 million to 270 million yuan for 2025 [1] - Seli Medical anticipates a net loss of 160 million to 209 million yuan for the 2025 fiscal year [1] Group 3 - Hongchuan Wisdom expects a full-year loss of 475 million to 443 million yuan for 2025 [1] - Various convertible bonds are listed, including Haomei Convertible Bond which will not be forcibly redeemed [2] - New stocks from Meidel and other companies are set to be listed on the Beijing Stock Exchange and Shanghai Stock Exchange [1]

Core Viewpoint - The company, Saily Medical (603716.SH), has announced a projected net loss for the fiscal year 2025, indicating a significant downturn in financial performance [1] Financial Performance - The expected net profit attributable to shareholders for 2025 is projected to be between -160 million RMB and -209 million RMB [1] - The anticipated net profit attributable to shareholders after deducting non-recurring gains and losses is estimated to be between -180 million RMB and -230 million RMB [1] Strategic Focus - The company is focusing on high-quality development by accelerating the construction of an integrated diagnostic and treatment technology platform driven by "AI + Smart Healthcare" and "Innovative Biopharmaceuticals" [1] - There is an ongoing effort to consolidate and enhance the company's comprehensive competitiveness in the smart healthcare sector [1]

Core Viewpoint - The company, Saily Medical, anticipates a net profit loss of between 160 million to 209 million yuan for the entire year of 2025, primarily due to strategic shifts and operational challenges [1]. Group 1: Reasons for Performance Change - The company is focusing on high-quality development by accelerating the construction of an integrated diagnostic and treatment technology platform driven by "AI + Smart Healthcare" and "Innovative Biopharmaceuticals" [2]. - A decline in operating revenue is attributed to the transfer of certain controlling subsidiaries to enhance asset operation efficiency, resulting in these subsidiaries no longer being included in the consolidated financial statements [2]. - The company is undergoing a strategic transformation, with some business contracts not being renewed after expiration, compounded by industry policy impacts, leading to a significant decrease in operating revenue [2]. Group 2: Impact of R&D and Impairments - Increased R&D investment in the smart healthcare sector has negatively impacted profits [3]. - The company has been enhancing its collection efforts on receivables, but extended payment cycles from some clients have led to credit impairment losses [3]. - A decline in revenue and profit from certain subsidiaries has prompted the company to recognize impairment losses on goodwill associated with these subsidiaries [3]. Group 3: Financial Performance Indicators - For the first three quarters of 2025, the company's main revenue was 857 million yuan, a year-on-year decrease of 39.64%, with a net profit attributable to shareholders of -87.24 million yuan, down 55.72% year-on-year [3]. - In Q3 2025, the company reported a single-quarter main revenue of 274 million yuan, a decrease of 38.41% year-on-year, and a net profit attributable to shareholders of -31.12 million yuan, an increase of 39.27% year-on-year [3]. - The company’s financial metrics include a debt ratio of 49.61%, investment income of 7.34 million yuan, financial expenses of 34.98 million yuan, and a gross profit margin of 21.73% [3].

Core Viewpoint - The company, Saily Medical, is expected to report a significant net loss for the year 2025, with projections indicating a loss between 160 million to 209 million RMB for net profit attributable to shareholders, and a loss between 180 million to 230 million RMB for net profit after deducting non-recurring gains and losses. This downturn is primarily attributed to a decline in operating revenue and increased R&D expenditures in the smart medical field [1][2]. Group 1: Financial Projections - The estimated net profit attributable to shareholders for 2025 is projected to be between -160 million to -209 million RMB [1] - The estimated net profit after deducting non-recurring gains and losses for 2025 is projected to be between -180 million to -230 million RMB [1] Group 2: Reasons for Performance Decline - The decline in operating revenue is due to the company's strategic decision to focus on core business development, resulting in the transfer of certain subsidiaries, which will no longer be included in the consolidated financial statements [1] - The company is undergoing a strategic transformation, and the lack of renewal arrangements for certain business contracts, combined with industry policy impacts, has led to a decrease in operating revenue [1] - Increased R&D investments in the smart medical field have negatively impacted profits due to higher R&D expenses [2]

Core Viewpoint - The company, Saili Medical, anticipates a net loss attributable to shareholders of between -160 million RMB and -209 million RMB for the fiscal year 2025, indicating a reduction in losses compared to the previous year [1] Group 1: Financial Performance - The expected net loss for 2025 represents a decrease in losses by 49.2397 million RMB to 2.397 million RMB year-on-year [1] - The primary reason for the performance change is a decline in operating revenue [1] Group 2: Strategic Changes - The company is undergoing a strategic transformation, which includes the transfer of part of its controlling subsidiaries, resulting in these subsidiaries no longer being included in the consolidated financial statements [1] - The decision to not renew certain business contracts after their expiration has also contributed to the decline in operating revenue [1] Group 3: Research and Development - The company is increasing its investment in research and development within the smart medical field, which is impacting profitability due to higher R&D expenses [1]

Financial Performance - The company expects a net profit attributable to shareholders for 2025 to be between -160 million RMB and -209 million RMB, indicating a decrease in loss by 49.24 million RMB to 23.97 million RMB year-on-year [4]. - The expected net profit attributable to shareholders after deducting non-recurring gains and losses for 2025 is projected to be between -180 million RMB and -230 million RMB, reflecting an increase in loss by 44.92 million RMB to 94.92 million RMB year-on-year [5]. - The total profit for the previous year (2024) was -148.30 million RMB, with a net profit attributable to shareholders of -209.24 million RMB [7]. Strategic Transformation - The company is undergoing a strategic transformation, leading to a decline in operating revenue due to the transfer of certain subsidiaries and the lack of renewal for some business contracts [8]. - Increased R&D investment in the smart medical field has impacted profits, contributing to the expected losses [9]. Receivables and Asset Assessment - The company is actively working on collecting receivables but has faced extended payment cycles from some clients, leading to credit impairment losses [10]. - There is an ongoing assessment of goodwill, long-term equity investments, and other asset values, with results yet to be determined [11]. - The company has not identified any significant uncertainties that could affect the accuracy of the earnings forecast [12].

Core Viewpoint - The company expects a net loss attributable to shareholders for the fiscal year 2025 to be between -160 million to -209 million yuan, indicating a reduction in loss compared to the previous year [1] Financial Performance - The projected non-recurring net profit is estimated to be between -180 million to -230 million yuan, which represents an increase in loss compared to the previous year [1] - The net profit for the same period last year was -209 million yuan [1] Reasons for Performance - The primary reasons for the expected loss include the transfer of part of the controlling subsidiary, expiration of business contracts without renewal, and industry policy impacts leading to revenue decline [1] - Increased research and development expenditures, as well as impairment of receivables and goodwill, are also contributing factors [1] - The valuation results of goodwill and other assets have not yet been determined, and final financial data will be based on the 2025 annual report [1]